News Hub | News Direct

All Industries

Article thumbnail News Release

Activate Games Inc. Announces Expansion with 30 New Stores in the UK and Ireland!


Activate Games Inc., the pioneering force behind the world's first active gaming experience, is thrilled to announce its expansive venture into the United Kingdom and Ireland markets with the opening of 30 new stores in partnership with We Do Play. Following the resounding success of Activate's innovative gaming concept across North America and the MENA region, the company is poised to revolutionize the entertainment landscape in the UK and Ireland. With a commitment to promoting physical activity while offering unparalleled gaming experiences, Activate is set to captivate audiences across these vibrant regions. "This expansion marks a significant milestone in Activate's journey," said Adam Schmidt, Founder and CEO of Activate Games Inc. "The UK and Ireland have long been on our radar as markets ripe for Activate's unique blend of interactive gaming and physical activity. We are excited to bring our adrenaline-pumping adventures to communities across these regions and provide an unforgettable entertainment experience for players of all ages." Each Activate location offers an immersive gaming environment where players can #EnterTheGame and compete in a variety of interactive challenges. Activate promises an experience like no other, where players can unleash their competitive spirit while staying active. "We are committed to diversifying leisure offerings and providing our guests with innovative entertainment experiences," said Richard Beese, Co-Owner of We Do Play. "With the launch of 30 new stores in the UK and Ireland, we are thrilled to introduce Activate to a new audience and create lasting memories for families, friends, and gaming enthusiasts alike." The expansion into the UK and Ireland marks a significant milestone in Activate's global growth strategy. Activate is poised to unveil more than 20 new stores across the United States and Canada in 2024, including an expansion into the MENA region this Fall. Furthermore, Activate has strategic plans for international growth, with aspirations to establish 70 stores in 10 countries over the next 5-10 years. With locations worldwide and a dedicated community of fans, Activate continues to push the boundaries of traditional entertainment and redefine the gaming experience for the modern era. For more information about Activate Games Inc. and to stay updated on the latest news and store openings, visit Activate or follow Activate on social media: Facebook: Activate Instagram: @activategames TikTok: @activategames ABOUT ACTIVATE Activate is the world’s first active gaming experience where players #EnterTheGame. Activate offers a unique blend of physical activity and gaming that promotes a healthy lifestyle. Each Activate location provides fun and interactive rooms for players to compete, earn stars and track achievements. With the global headquarters located in Winnipeg, Canada, Activate has grown to 30 locations across Canada, the U.S. and now the world! To join the active gaming movement, visit ABOUT WE DO PLAY We Do Play specializes in creating unforgettable, immersive leisure and hospitality concepts. It started as a single brand, eventually incorporating Flip Out and Putt Putt Social. Boom Battle Bar was also previously co-owned by We Do Play. Flip Out is a global indoor adventure park business and is currently the largest in the UK. Since 2015, Flip Out has catered to 8 million customers a year. Putt Putt Social is the UK’s leading Asian-inspired adventure golf, drink and dining experience. We Do Play is continuing to expand its footprint in the leisure and entertainment space, with its partnership with Activate being the latest addition to its portfolio. Follow We Do Play on Linkedin: We Do Play Follow Flip Out on Instagram: @flipoutuk Follow Putt Putt Social on Instagram: @puttputtsocial Contact Details Jalila Singerff +1 613-614-6777 Company Website

May 28, 2024 08:02 AM Eastern Daylight Time

Article thumbnail News Release

Baron Oil Proposes Name Change to Sunda Energy, Reports Year-End Financial Results

Baron Oil PLC

Baron Oil CEO Dr Andy Butler joined Steve Darling from Proactive to announce the company's proposal to change its name to Sunda Energy plc. This new name reflects the company’s strategic focus on gas exploration and production in Southeast Asia, particularly in the Sunda region, a vast archipelago known for its rich natural resources. The Board believes the company holds significant competitive advantages in this region, including a robust operating platform, a team with considerable experience and a stellar reputation, strong relationships with government and industry peers, and extensive regional knowledge that will enable the execution of a clear, value-oriented growth strategy. Butler also detailed the company’s year-end financial results, highlighting several major milestones achieved over the past year. Notably, Baron Oil has made substantial progress with the Chuditch asset in Timor-Leste, moving from the evaluation phase into drilling preparation. Chuditch, estimated to hold 1.2 trillion cubic feet of gas and 200 million barrels of oil equivalent. The drilling is planned for early next year, with preparations well underway. Additionally, Baron Oil secured a farm-up agreement with TIMOR GAP, Timor-Leste's national oil company, completed after the reporting period. This agreement increased TIMOR GAP's working interest in the Chuditch project from 25% to 40%, with TIMOR GAP now responsible for 20% of the Production Sharing Contract (PSC) costs. This strategic partnership not only strengthens the project's financial foundation but also aligns with regional development goals. The company remains focused on securing additional funding partners to participate in the drilling of the appraisal well. This effort is crucial for advancing the Chuditch project and realizing its full potential. The name change to Sunda Energy plc is seen as a pivotal step in aligning the company's identity with its strategic ambitions and regional focus. In conclusion, Baron Oil's proposed name change to Sunda Energy, combined with its significant achievements over the past year, positions the company for continued growth and success in the Southeast Asian gas sector. The company’s strategic focus, robust partnerships, and strong regional presence are expected to drive future developments and enhance shareholder value. Contact Details Proactive UK +44 20 7989 0813

May 28, 2024 07:23 AM Eastern Daylight Time

Article thumbnail News Release

Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics

RazorPitch CRDL

Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, has been attracting substantial interest from investors looking for opportunities in the biotech sector. CRDL is currently developing CardiolRx™ and CRD-38 therapies for heart diseases, including recurrent pericarditis, acute myocarditis, and heart failure. Over the past year, CRDL stock has surged by more than 250%, illustrating the increasing level of investor interest in the company. The stock now trades around $2.35 per share and appears to be on track to test its next potential resistance at $3. For investors who may be wondering whether they missed out on Cardiol Therapeutics' (NASDAQ:CRDL) (TSX:CRDL) impressive rally, here’s some good news. The stock has the potential for further upside considering the fact that Cardiol will release topline data for its Phase 2 MAvERIC-Pilot clinical trial evaluating the efficacy of CardiolRx™ for the treatment of recurrent pericarditis sometime in early June, which, if positive, has the potential to send the stock higher. Moreover, several analysts have reiterated that the stock has the potential for significant upside, further reaffirming Cardiol’s growth prospects. For instance, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial. According to Gantoss, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has many things going in its favor right now heading into a critical Phase 2 trial readout in recurrent pericarditis in June that he believes will lead to a positive outcome. Those include a strong rationale for its mechanism of action as well as receipt of FDA Orphan Drug Designation (ODD), which suggests a positive signal in an early data subset, plus a tried-and-true recurrent pericarditis trial design with experienced investigators at the helm. Thanks to the FDA ODD grant, CardiolRx™ has a clear path to expedite the development timeline and will ensure a market exclusivity period of at least 7 years. And the great thing is that there’s a robust market for innovation in this indication, as evidenced by a successful recent drug launch. At a current market cap of $162 million, this is clearly underappreciated and unrecognized by the market at the present time. For reference, company peer Kiniksa Pharmaceuticals (KNSA) now has a $1.4 billion market cap on expected sales of $360-$380 million for treating recurrent pericarditis, with single to low double-digit market penetration. We also note the example of Jazz Pharmaceuticals (JAZZ) buying out company peer GW Pharma (GWPH) for approximately $7 billion after Epidiolex, a formulation sharing a similar active ingredient with CardiolRx™, reached half a billion in sales in epilepsy over 2 years (now guiding for a US $1-billion-dollar franchise in the years to come). “Clearly, a $160 million market cap does not do Cardiol justice. With positive data in Q2, the path to market becomes a slam dunk, and the stock should surge to the upside in response,” says Gantoss. In addition, analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and issued a $9 price target, which implies that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from current levels. There is currently only one FDA-approved therapy for recurrent pericarditis. With CardiolRx™’s strong safety profile vs. anti-inflammatory and immunosuppressive drugs, the analyst believes CardiolRx™ has the potential to be a safe, new approach to recurrent pericarditis treatment and is underappreciated. Likewise, Bernardino also expects topline results from MAvERIC-Pilot to be a positive catalyst in early June. ARCHER is Cardiol’s Phase 2 multi-center, international, double-blind, randomized, placebo-controlled trial investigating the safety, tolerability, and impact of CardiolRx™ on myocardial recovery in patients presenting with acute myocarditis. ARCHER trial design, rationale, and blinded baseline data on the first 50 patients randomized were the subject of an oral presentation at the World Congress on Acute Heart Failure earlier this month. According to Bernardino, they are positive about the results as they look for ARCHER to assist in furthering understanding of the therapeutic potential of CardiolRx™ and complement the MAvERIC-Pilot Phase 2 study. ARCHER patient recruitment has been accelerating, with the trial expected to enroll 100 patients in the United States, Canada, France, Brazil, and Israel. In fact, ARCHER has now exceeded 85% of target enrollment, and as a result, H.C. Wainwright & Co. believes prospects for its completion by early 2025 are good. Huge unmet medical need Pericarditis is a heart disorder consisting of inflammation of the pericardium, the membrane or sac that surrounds the heart and protects it from damage during contraction. Acute pericarditis lasts about 4-6 weeks before resolving, but often patients can experience a second episode. If another episode occurs following a period of 4-6 weeks without symptoms, this is considered recurrent pericarditis. At the moment, the first-line conventional treatment for recurrent pericarditis is NSAIDs or aspirin, with or without colchicine. For the second-line therapy, for patients with continued recurrence and inadequate response, corticosteroids are administered despite safety issues and difficulty tapering or discontinuation. The only FDA-approved therapy, ARCALYST® (rilonacept) averages over $150,000 per year and is primarily used for over three recurrences. The most common complication of pericarditis is recurrence, occurring in 15-30% of first-time pericarditis cases, some complications can be deadly, and an estimated 5% of all hospitalizations for chest pain in the US and Europe are due to pericarditis. In the US, the annual prevalence is about 160,000 cases (based on 40/100,000) which includes 38,000 cases with a recurrence. Hospitalization costs average $20 – $30k with a 6 – 8-day length of stay. So far, ARCALYST® has had impressive results in recurrent pericarditis and strong market uptake since its launch in 2021, and this is bullish for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) since it reflects a market in need of innovation and ready to embrace new alternatives. Takeaway In summary, the near-term pericarditis clinical proof-of-concept data expected in early June could be a major catalyst and turning point for Cardiol and its valuation. Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a strong financial position, being debt-free and is well-capitalized to achieve corporate milestones into 2026, which is why analysts remain confident in the company’s long-term growth prospects. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cardiol Therapeutics to assist in the production and distribution of content related to CRDL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 Company Website

May 28, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Polymetals Resources secures $5 million investment from Metals Acquisition for Endeavor Mine

Polymetals Resources Ltd

Polymetals Resources Ltd (ASX: POL) managing director Dave Sproule joins Proactive’s Jonathan Jackson to discuss a non-exclusive strategic alliance with Metals Acquisition Ltd (ASX: MAC). This partnership aims to enhance value extraction from the Endeavor Mine and CSA Copper Mine, in the Cobar Basin, NSW, Australia. As part of this alliance, MAC will invest up to $5 million in Polymetals at $0.35 per share. The two companies will enter into an agreement to treat high-grade zinc ore from MAC’s CSA mine at Polymetals' Endeavor Silver-Zinc Mine. Additionally, Polymetals will provide MAC with excess water offtake, which will help increase the ore treatment capacity at the CSA mine. The strategic alliance is designed to exploit operational synergies between these neighbouring mines, with the goal of enhancing production and financial outcomes. Sproule, expressed confidence in the partnership, highlighting the benefits for all stakeholders. He noted that Polymetals had operated in the Cobar Basin for many years and that the collaboration with MAC was expected to unlock significant value through existing synergies and other opportunities as the relationship develops. He emphasised that bringing the Endeavor Mine back into production would be a positive outcome for NSW and the Cobar community, creating more than 200 direct jobs and injecting around $50 million a year into the local economy for at least the next 10 years. He also mentioned the potential to extend the mine's life through ongoing optimisation, exploration success, and value-adding treatment options. With the ability to defer the environmental bond replacement for up to two years and taking full ownership of the Endeavor Silver-Zinc Mine operating assets, Polymetals is now positioned to complete the optimisation and restart financing for the mine. The company plans to commence refurbishment works in early H2 2024, with the first concentrate output expected during H1 2025. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744

May 27, 2024 06:45 PM Eastern Daylight Time

Article thumbnail News Release

Intra Energy Corporation approved for lithium and gold drilling at Maggie Hays Hills


Intra Energy Corporation Ltd (ASX: IEC) managing director Ben Dunn sits down with Proactive’s Jonathan Jackson after the WA Department of Energy, Mines, Industry Regulation and Safety (DEMIRS) approved IEC's Program of Works (PoW). The company now plans to conduct 2,500 metres of reverse circulation (RC) drilling for lithium, tantalum, niobium and caesium pegmatites at the Maggie Hays Hills Project in Western Australia. These pegmatites are believed to be up to 50 metres wide, with outcroppings along a 2.5-kilometre contact zone. Additionally, IEC aims to drill test several outcropping quartz reefs, where rock chip samples have shown gold results of up to 17 g/t, extending over a 1.5-kilometre geological contact zone. According to Dunn, the approval is a significant step towards the drilling phase, with multiple promising lithium pegmatite and gold targets identified. IEC is collaborating with the Ngadju Native Title Group to secure the necessary heritage clearance, expected to be surveyed by late May, with drilling anticipated to start by mid-June, pending clearance. Pending laboratory assays for 50 infill soil samples and 12 rock samples are expected within the next two weeks. The heritage survey is scheduled for May 30, 2024, and track clearing at Maggie Hays is planned for early June. Contact Details Proactive Investors Proactive Investors +61 413 713 744

May 27, 2024 06:40 PM Eastern Daylight Time

Article thumbnail News Release

Aruma Resources acquires copper and uranium assets in game-changing play

Aruma Resources Ltd

Aruma Resources Ltd (ASX: AAJ) managing director Glenn Grayson sits down with Jonathan Jackson in the Proactive studio to talk about the “game-changing” acquisition of a portfolio of copper and uranium exploration assets located in tier-1 mineral precincts in South Australia and Queensland. The assets include the Wilan IOCG-Uranium Project in the Olympic Dam precinct of South Australia and the Fiery Creek Copper Project and Bortala Copper Project in the Mt Isa region of Queensland. These projects offer potential for copper-gold discoveries (stratiform and IOCG), as well as uranium targets at the Wilan Project. As part of the acquisition, Aruma will issue NHM Holdings (Australia) Pty Ltd (NHMHA) shareholders 26.5 million fully paid AAJ ordinary shares, which will be under a six-month voluntary escrow. Additionally, Aruma will grant 24.5 million non-transferable options exercisable into one ordinary AAJ share upon securing drilling approvals at the Wilan Project and 28 million options exercisable into one ordinary AAJ share upon reporting a significant drill intercept. Furthermore, a 2% Net Smelter Return (NSR) will be paid to NHMHA shareholders on any minerals extracted and sold from the new projects. The due diligence on the projects has been successfully completed and the acquisition is pending Aruma shareholder approval. Post-acquisition, Aruma plans to initiate targeted field work programs to define and drill test priority targets. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744

May 27, 2024 06:35 PM Eastern Daylight Time

Article thumbnail News Release

Gold Hydrogen achieves record purity levels in Stage 1 testing


Gold Hydrogen Ltd (ASX:GHY) managing director Neil McDonald sits down with Jonathan Jackson in the Proactive studio to discuss the completion of Stage 1 well testing at its Ramsay Project on the Yorke Peninsula of South Australia, achieving exceptional results. The Ramsay 1 and Ramsay 2 wells recorded world-leading purity levels of 17.5% helium and 95.8% natural hydrogen (air corrected). This marks the first dedicated natural hydrogen and helium well-test operation in Australia, and one of the few globally. The Ramsay 1 test utilised an open hole well test to assess formation inflow, with nitrogen injection used to clear fluids. Formation permeability was indicated by fluid influx and natural hydrogen recovery at the surface. The Ramsay 2 test involved detailed testing of seven zones, identified using open hole logs and mud gas data from prior drilling. All zones confirmed natural hydrogen at the surface, validating previous purity levels, with the highest at 531 metres depth. Helium was also extracted from a 180-metre thick zone in the Kulpara Dolomite, with significant spikes during initial testing, confirming 17.5% helium purity. The primary objective of confirming downhole pressure and natural gas flow to the surface was achieved. Stage 2 will involve extended well testing to determine flow rates, involving a downhole pump to remove formation fluid. Success in this phase will inform future well designs and contribute to a pilot plant design. McDonald highlighted the significance of these results, which are among the highest purity levels recorded globally. Stage 2 testing is planned to begin in early Q3 2024, aiming for commercial production of natural hydrogen and helium. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744

May 27, 2024 06:30 PM Eastern Daylight Time

Article thumbnail News Release

Compumedics set for record-breaking $46 million FY24 revenue

Compumedics Limited

Compumedics Ltd (ASX:CMP) CFO and company secretary David Lawson talks to Proactive’s Jonathan Jackson about the company’s record revenues of at least $46 million for FY24, with sales orders exceeding $50 million. The company anticipates a profit for FY24 due to strong sales performance. Compumedics has projected record sales orders and revenues for FY24 driven by strong growth in its Australian sleep and neurodiagnostic businesses. The company has received new MEG orders and has seen increased European sales, particularly boosted by the Okti wireless EEG amplifier. In the USA, sales growth reached 60% in H2 FY24. Compumedics reported an H1 FY24 EBITDA of $2.2 million, though there is uncertainty in meeting the prior guidance of $5 million due to investments in the US sales and marketing team and delays in resuming DWL's China business. In the Somfit commercialisation update, Compumedics expects SaaS revenue to exceed $4 million for FY24, up from $1.7 million in FY23. Sales have commenced in the USA following FDA approval, with initial revenues invoiced in Q4 FY24. Both Somfit and Nexus 360 show significant revenue growth. For MEG, the installation at Tianjin Normal University in China is expected to be completed soon, with two additional MEG sales planned for 2025. These sales represent about $14 million in new orders. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744

May 27, 2024 03:45 PM Eastern Daylight Time

Article thumbnail News Release

Prodigy Disc Announces the Launch of the MX-2 Midrange Disc

Rev Up Marketers

Prodigy Disc, a renowned innovator in the world of disc golf, has introduced a new addition to its lineup: the MX-2, an overstable midrange disc designed for high performance and reliability under various playing conditions. The launch of the MX-2 continues Prodigy Disc’s commitment to innovation and quality in the disc golf market. By expanding their product range with discs like the MX-2, Prodigy aims to cater to a broad spectrum of player preferences and skills. Disc golfers can look forward to experiencing the MX-2 on courses around the world as it becomes available through various sports outlets and online platforms. About Prodigy Disc: Prodigy Disc is a premier disc golf company dedicated to the sport's innovation and enhancement. Founded by Disc Golf World Champions, Prodigy Disc produces consistent, high-quality discs designed to improve flight distance and accuracy for players of all skill levels. Since launching their first line of discs in 2013 to critical acclaim, Prodigy has expanded their offerings to include a wide variety of discs and has sponsored over 150 elite players. In addition to discs, Prodigy Disc provides top-tier equipment, accessories, and apparel, all crafted with input from professional athletes to meet the specific needs of the disc golf community. Contact Details Prodigy Disc Ben Rosenberg +1 706-671-1210 Company Website

May 27, 2024 01:46 PM Eastern Daylight Time

1 23456 ... 3585